treatment diabetes atherosclerosis inhibiting fatty-acid-binding protein ap2 
adipocyte fatty-acid-binding protein ap2 fabp4 expressed adipocytes macrophages integrates inflammatory metabolic responses studies ap2-deficient mice shown lipid chaperone significant role several aspects metabolic syndrome including type diabetes atherosclerosis demonstrate orally active small-molecule inhibitor ap2 effective therapeutic agent severe atherosclerosis type diabetes mouse models macrophage adipocyte cell lines without ap2 also show target specificity chemical intervention mechanisms action metabolic inflammatory pathways findings demonstrate targeting ap2 small-molecule inhibitors possible can lead new class powerful therapeutic agents prevent treat metabolic diseases type diabetes atherosclerosis 
